

Remarks

Claims 1 to 15 are pending in the present application and are rejected.

Claims 1 to 15 are cancelled.

New claims 16 to 29 are presented for examination.

Claim Rejections Under 35 U.S.C. § 112

Claims 1-15 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1-15 are cancelled and rewritten to correct each of the issues cited by the Examiner. Accordingly, the rejection under 35 U.S.C. § 112, second paragraph is now moot.

Claim Rejections Under 35 U.S.C. § 103

Claims 1-8, 10-12, 14-15 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Trage et al. (US 2002/0111280 A1).

Claims 1-8, 10-15 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Trage et al. (US 2002/0111280 A1) as applied to claims 1-8, 10-12, 14-15 above, and further in view of Knoll et al. (US 4822604).

Claims 1-15 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Trage et al. (US 2002/0111280 A1) and Knoll et al. (US4822604) as applied to claims 1-8, 10-15 above, and further view of Gehlsen (US 2001/0018059A1).

Independent claims 16 and 29 provide a specific combination of vanilla extract, a quaternary ammonium, and a cationic chloride salt. In particular, the composition contains less than 2% vanilla extract, from about 0.001% to about 40% of quaternary ammonium, and from about 0.001% to about 10% of a cationic chloride salt. The amount of vanilla extract is of particular significance. This is clearly stated in the specification which states:

[0016] In the present invention it has been found that when vanilla extract is used in the cleansing liquid where quantity is very minimal (say <2%) it exhibits an anti-allergic and anti-inflammatory effect on the skin in patients who suffer with psoriasis.

The present invention provides an unexpected significant relief of psoriasis occurring at a very low concentration of vanilla extract. Significantly none of the references cited by the extract provide such an effect. Moreover, none of the references provide the specific combination of vanilla extract, a quaternary ammonium, and a cationic chloride salt provided by independent claims 16 and 29.

Accordingly, for at least these reasons new claims 16-29 are allowable under 35 U.S.C. § 103(a).

Conclusion

Applicants have made a genuine effort to respond to each of the Examiner's rejections in advancing the prosecution of this case. Applicants believe that all formal and substantive requirements for patentability have been met and that this case is in condition for allowance, which action is respectfully requested. If a telephone or video conference would help expedite allowance or resolve any additional questions, such a conference is invited at the Examiner's convenience.

The fee for the two month extension of time in the amount of \$230.00 is being filed electronically herewith. Please charge any additional fees or credit any overpayments as a result of the filing of this paper to our Deposit Account No. 02-3978.

Respectfully submitted,
Medasani Munisekhar

By /James W. Proscia/
James W. Proscia
Reg. No. 47,010
Attorney/Agent for Applicant

Date: June 3, 2008

BROOKS KUSHMAN P.C.
1000 Town Center, 22nd Floor
Southfield, MI 48075-1238
Phone: 248-358-4400
Fax: 248-358-3351